Related Experiment Video
Updated: Apr 28, 2026
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Yang Zhang1, Ke-Jie Li1, Can Wang1
1Department of Radiotherapy, the First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, China.
Abstract:
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.
Insights
A novel XPO1-ALK fusion was identified in non-small cell lung cancer (NSCLC). Brigatinib treatment led to tumor disintegration and partial remission, demonstrating efficacy in this ALK-positive NSCLC case.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Anaplastic Lymphoma Kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients benefit from ALK tyrosine kinase inhibitors (TKIs).
- Identifying novel ALK fusions is crucial for expanding treatment options in advanced NSCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...